Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis
Yejin Mok, Aditya Surapaneni, Yingying Sang, Josef Coresh, Morgan E. Grams, Kunihiro Matsushita, Shoshana H. Ballew, Natalia Alencar de Pinho, Johan Ärnlöv, Sandhi Maria Barreto, Samira Bell, Hermann Brenner, Juan Jesús Carrero, Rajkumar Chinnadurai, Elizabeth L. Ciemins, Ron T. Gansevoort, Simerjot K Jassal, Keum Ji Jung, H. Lester Kirchner, Tsuneo Konta, Csaba P. Kövesdy, Li Luo, Krutika Pandit, Mahboob Rahman, Cassianne Robinson‐Cohen, Charumathi Sabanayagam, Ulla T. Schultheiß, Michael G. Shlipak, Natalie Staplin, Marcello Tonelli, Angela Yee‐Moon Wang, Chi Pang Wen, Mark Woodward, Jennifer S. Lees, Katie Harris, Hisatomi Arima, John Chalmers, Morgan E. Grams, Elvis A. Akwo, Jing He, Anita Lloyd, Natália Alencar de Pinho, Marie-Hélène Metzger, Bénédicte Stengel, Aghilès Hamroun, Ziad A. Massy, Panduranga S. Rao, Nestor Sosa, Vallabh O. Shah, Jesse Y. Hsu, Álvaro Vigo, José Geraldo Mill, Paulo A. Lotufo, Scheine Canhada, Ben Schöttker, Hannah Stocker, Dietrich Rothenbacher, Markus P. Schneider, Anna Köttgen, Heike Meiselbach, Kai‐Uwe Eckardt, Jamie Green, Alex R. Chang, Gurmukteshwar Singh, Emilie Lambourg, Shona Livingstone, Ewan R. Pearson, Sun Ha Jee, Heejin Kimm, Ronit Katz, Carina Flaherty, Jeff T. Mohl, Lyanne M. Kieneker, Stephan J. L. Bakker, Bert van der Vegt, Rudolf A. de Boer, Jaclyn Bergstrom, Joachim H. Ix, Keiichi Sumida, Prabin Shrestha (2025). Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis. , 133(10), DOI: https://doi.org/10.1038/s41416-025-03140-z.
Article45 days agoImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, Natalie Staplin, KJ Mayne, Christoph Wanner, Julie Green, SJ Hauske, Jonathan Emberson, David Preiss, SYA Ng, AJ Roddick, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, Susanne Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Daisy Massey, Martin Landray, Colin Baigent, Richard Haynes, WG Herrington, S Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masanori Abe, Nader G. Abraham, Sarah Acheampong, P Achiri, JA Acosta, A. Q. Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, Movahedian Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, A. Aitken, R AitSadi, Sendogan Aker, S Akimoto, A Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Leslie N. Aldrich, M Alegata, Lee Alexander, S Alfaress, Mohammad Alhadj Ali, Ahmed Issam Ali, Ahmed Issam Ali, Radica Z. Alicic, A Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, Mora Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, Kwame Ansu, A Apostolidi (2023). Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. , 12(1), DOI: https://doi.org/10.1016/s2213-8587(23)00322-4.
Article44 days agoImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, Natalie Staplin, KJ Mayne, Christoph Wanner, Julie Green, SJ Hauske, Jonathan Emberson, David Preiss, SYA Ng, AJ Roddick, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, Susanne Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Daisy Massey, Martin Landray, Colin Baigent, Richard Haynes, WG Herrington, S Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masanori Abe, Nader G. Abraham, Sarah Acheampong, P Achiri, JA Acosta, A. Q. Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, Movahedian Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, A. Aitken, R AitSadi, Sendogan Aker, S Akimoto, A Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Leslie N. Aldrich, M Alegata, Lee Alexander, S Alfaress, Mohammad Alhadj Ali, Ahmed Issam Ali, Ahmed Issam Ali, Radica Z. Alicic, A Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, Mora Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, Kwame Ansu, A Apostolidi (2023). Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. , 12(1), DOI: https://doi.org/10.1016/s2213-8587(23)00322-4.
Article44 days agoImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, Natalie Staplin, KJ Mayne, Christoph Wanner, Julie Green, SJ Hauske, Jonathan Emberson, David Preiss, SYA Ng, AJ Roddick, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, Susanne Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Daisy Massey, Martin Landray, Colin Baigent, Richard Haynes, WG Herrington, S Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masanori Abe, Nader G. Abraham, Sarah Acheampong, P Achiri, JA Acosta, A. Q. Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, Movahedian Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, A. Aitken, R AitSadi, Sendogan Aker, S Akimoto, A Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Leslie N. Aldrich, M Alegata, Lee Alexander, S Alfaress, Mohammad Alhadj Ali, Ahmed Issam Ali, Ahmed Issam Ali, Radica Z. Alicic, A Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, Mora Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, Kwame Ansu, A Apostolidi (2023). Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. , 12(1), DOI: https://doi.org/10.1016/s2213-8587(23)00322-4.
Article44 days agoEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Natalie Staplin, Richard Haynes, PK Judge, Christoph Wanner, Julie Green, Jonathan Emberson, David Preiss, KJ Mayne, SYA Ng, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Siegfried Seidi, Martin Landray, Colin Baigent, WG Herrington, Sharirose Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masami Abe, Ned Abraham, Sarah Acheampong, P Achiri, JA Acosta, A A Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, Ahmad Mukhtar, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, Alastair Aitken, R AitSadi, Sendogan Aker, S Akimoto, Akinwande A. Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Luke Aldrich, M Alegata, Lacy M. Alexander, S Alfaress, Mohammad Alhadj Ali, Radica Z. Alicic, Arta Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, M. Ochoa de Olza Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, K Ansu, A Apostolidi, N. Arai (2023). Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. , 12(1), DOI: https://doi.org/10.1016/s2213-8587(23)00321-2.
Article44 days ago